Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DISC-3405 in Sickle Cell Disease
NCT07187973Phase 1Recruiting
- Sponsor
- Disc Medicine
- Start
- Jan 2026
- Primary completion
- Jun 2027
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of DISC-3405 in sickle cell disease (SCD), sponsored by Disc Medicine. Primary endpoint: Safety and tolerability of DISC-3405 administration up to 36 weeks. Started Jan 2026; status: recruiting.
02
Drugs
DISC-3405
03
Conditions
sickle cell disease (SCD)
Beyond the preview
Go deeper on NCT07187973.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07187973.